Niagen Bioscience, Inc., a prominent leader in NAD+ (nicotinamide adenine dinucleotide) research focused on healthy aging, has shared promising results from a groundbreaking clinical trial. The study, published in The Lancet journal eClinicalMedicine, reflected that taking Niagen® (a patented form of nicotinamide riboside, or NR) daily catered to the increase in NAD+ levels as well as improved executive function, fatigue, depression, and sleep quality in some people with long COVID (also called PASC), compared to their baseline digital health levels.
The study involved 58 participants and was randomized, double-blind, and placebo-controlled. It was led by Dr. Edmarie Guzmán-Vélez, who was previously an Assistant Professor in the Department of Psychiatry and the McCance Center for Brain Health at Massachusetts General Hospital. She is now an Assistant Professor in the Department of Neurology at Robert Wood Johnson Medical School and the Center for Health Aging Research (CHAR) at Rutgers University.
This 24-week study looked at how increasing NAD+ levels with Niagen NR supplements affected recovery from long COVID symptoms, including cognitive issues. The study involved 58 adults (average age 45.1 years) who still had symptoms after a COVID-19 infection. Participants were randomly assigned to either take Niagen NR (2,000 mg/day) for 20 weeks or a placebo for 10 weeks, then switch to Niagen NR for the final 10 weeks. The study also included a two-week placebo period at the start and a two-week follow-up period at the end.
Executive Statement
According to Rob Fried, Chief Executive Officer of Niagen Bioscience, these findings demonstrate that ten weeks of Niagen NR supplementation increased NAD+ levels and improved long COVID symptoms of fatigue, sleep quality, and depression, compared to symptoms before treatment. As part of their mission to advance the science of cellular health, they are pleased to see Niagen NR used in research exploring the lasting impact of COVID-19 and look forward to future studies that further their understanding of NAD+ augmentation in recovery and resilience.